Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang(Tongji Hospital), Gordon B. Mills(The University of Texas MD Anderson Cancer Center), Yiling Lu(The University of Texas MD Anderson Cancer Center), Imelda Mercado‐Uribe(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Guang Peng(The University of Texas MD Anderson Cancer Center), Shiaw‐Yih Lin(The University of Texas MD Anderson Cancer Center), Marilyne Labrie(Université de Sherbrooke), Steven W. Wang(Center for Systems Biology), Mark J. O’Connor(AstraZeneca (United Kingdom)), Daniel J. McGrail(Cleveland Clinic), Nidhi Sahni(The University of Texas MD Anderson Cancer Center), Hui Dai(The University of Texas MD Anderson Cancer Center), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Chaoyang Sun(Tongji Hospital), Sanghoon Lee(The University of Texas MD Anderson Cancer Center), Yongsheng Li(Tongji Hospital), Ken Chen(Center for Personalized Cancer Treatment), Xiaohua Chen(Fujian Medical University), Jinsong Liu(Guangzhou Institutes of Biomedicine and Health), Zhenlin Ju(The University of Texas MD Anderson Cancer Center), Zhiyong Ding(Baotou Research Institute of Rare Earths), Jiyong Liang(The University of Texas MD Anderson Cancer Center), Tae-Beom Kim(The University of Texas MD Anderson Cancer Center), Dong Zhang(Fudan University), Kang Jin Jeong(The University of Texas MD Anderson Cancer Center), Christopher P. Vellano(The University of Texas MD Anderson Cancer Center)
Cited by 243
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k